Clinical Trials

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07049926 2026-02-19

MK-3475-03C

Phase 1/2 Recruiting

140 enrolled

Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Phase 1/2 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04626479 2026-02-12

MK-3475-03A

400 enrolled

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07405164 2026-02-12

MK-6482-043

450 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05468697 2026-01-23

MK-6482-024

60 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

80 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

10 enrolled

Carcinoma, Renal Cell

NCT06428396 2025-12-26

LITESPARK-029

120 enrolled

Breast

Breast Neoplasms

NCT05030506 2025-12-18

MK-6482-010

45 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

249 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

32 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

Phase 1 Recruiting

12 enrolled

Clear-cell metastatic renal cell carcinoma

NCT07167329 2025-09-11

BELIEVE-VHL

CNSEndocrineGenitourinary

100 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT05239728 2025-08-14

MK-6482-022

1,800 enrolled

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2025-07-25

KEYMAKER-U03

370 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04627064 2025-07-25

ABEMA Alone or in COMBO With MK-6482

Phase 1 Completed

11 enrolled 9 charts

Carcinoma, Renal Cell

NCT02974738 2025-07-10

MK-6482-001

Phase 2 Not yet recruiting

120 enrolled

CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

NCT07023432 2025-06-17

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

78 enrolled

Carcinoma, Renal Cell

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04976634 2025-04-06

MK-6482-016

730 enrolled

Tumor-Agnostic

Neoplasms

NCT04489771 2025-02-11

MK-6482-013

154 enrolled 19 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03634540 2024-12-20

MK-6482-003

118 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT03401788 2024-12-03

MK-6482-004

50 enrolled 1 FDA

von Hippel-Lindau Disease

NCT04846920 2024-11-22

MK-6482-018

52 enrolled

Carcinoma, Renal Cell

NCT04736706 2024-11-18

MK-6482-012

1,653 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02293980 2024-06-17

MK-3795-001

110 enrolled